1. Scrip
  2. >>Business
  3. >>Earnings

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

 
• By Jessica Merrill

Pfizer’s management team addressed topics ranging from COVID-19 revenues to Medicare’s drug negotiation program and new product launches.

Pfizer reported first quarter financial results • Source: Shutterstock

Pfizer Inc. is continuing in a transition phase as it integrates the Seagen oncology business, right-sizes the COVID-19 business and builds commercial momentum behind newer drugs and vaccines across a wide array of therapeutic areas. It’s an important year for Pfizer to rebuild trust with investors after a disappointing 2023, when the company missed its financial forecast and had to reset expectations late in the year and implement cost cuts.

Key Takeaways
  • Pfizer reported a 20% first quarter revenue decline driven by lower COVID-19 sales, but sales grew 11% operationally excluding the vaccine Comirnaty and antiviral Paxlovid.
  • The...

“We know credibility is extremely important for us,” CEO Albert Bourla told investors during the company’s first quarter sales and earnings call on 1 May. After the misalignment on COVID-19...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

More from Business

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.